Cholinergic Functioning in Stimulant Addiction: Implications for Medications Development
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Acetylcholine, the first neurotransmitter discovered, participates in many CNS functions, including sensory and motor processing, sleep, nociception, mood, stress response, attention, arousal, memory, motivation and reward. These diverse cholinergic effects are mediated by nicotinic- and muscarinic-type cholinergic receptors (nAChR and mAChR, respectively). The goal of this review is to synthesize a growing literature that supports the potential role of acetylcholine as a treatment target for stimulant addiction. Acetylcholine interacts with the dopaminergic reward system in the ventral tegmental area, nucleus accumbens and prefrontal cortex. In the ventral tegmental area, both nAChR and mAChR stimulate the dopaminergic system. In the nucleus accumbens, cholinergic interneurons integrate cortical and subcortical information related to reward. In the prefrontal cortex, the cholinergic system contributes to the cognitive aspects of addiction. Preclinical studies support a facilitative role of nicotinic receptor agonists in the development of stimulant addiction. In contrast, nonselective muscarinic receptor agonists seem to have an inhibitory role. In human studies, acetylcholinesterase inhibitors, which increase synaptic acetylcholine levels, have shown promise for the treatment of stimulant addiction. Further studies testing the efficacy of cholinergic medications for stimulant addiction are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Synaptic plasticity and addiction
Kauer, J. A., & Malenka, R. C. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2234 · Cited by 1,397 · cited 1×
“These signalling cascades are essential for many neuronal functions, including neuronal differentiation, survival and synaptic plasticity, which also play an important role in addiction.([16-18]) The M1, M4 and M5 mAChR subtypes are predominantly expressed in the CNS, whereas the M2 and M3 mAChR subtypes are found bot…”
BackgroundNicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System
Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Dramatic decreases in brain reward function during nicotine withdrawal
Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998) · Nature · doi:10.1038/30001 · Cited by 674 · cited 1×
“Nicotine withdrawal has been shown to reduce brain reward function in rats, which may also be mediated by a4, b2 or a7 subunits.([26])”
BackgroundAbnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain
Picciotto, M. R., Zoli, M., Léna, C., Bessis, A., Lallemand, Y., LeNovère, N., Vincent, P., Pich, E. M., Brûlet, P., & Changeux, J.-P. (1995) · Nature · doi:10.1038/374065a0 · Cited by 668 · cited 1×
“b2-Containing receptors are critical for the addictive as well as the cognitive performance-enhancing properties of nicotine.([24,25]) Nicotine withdrawal has been shown to reduce brain reward function in rats, which may also be mediated by a4, b2 or a7 subunits.”
BackgroundTargeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Wess, J., Eglen, R. M., & Gautam, D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2379 · Cited by 637
Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity
Gu, Q. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00026-x · Cited by 518
Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
Di Chiara, G., Morelli, M., & Consolo, S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90005-1 · Cited by 467 · cited 3×
“[29] GABA is the main inhibitory neuron in the brain, and the output neurons in the nucleus accumbens (medium spiny neurons) are GABAergic.”
Background
Cited by
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
“The primary muscarinic subtypes in the striatum are M1 and M4 (Sofuoglu and Mooney, 2009).”
Muscarinic acetylcholine receptors: novel opportunities for drug development
Kruse, A. C., Kobilka, B. K., Gautam, D., Sexton, P. M., Christopoulos, A., & Wess, J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4295 · Cited by 437
Sex differences in the neural mechanisms mediating addiction: a new synthesis and hypothesis
Becker, J. B., Perry, A. N., & Westenbroek, C. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-14 · Cited by 317
Cognitive Effects of Nicotine: Recent Progress
Valentine, G., & Sofuoglu, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171103152136 · Cited by 271
Self-citationCognitive function during nicotine withdrawal: Implications for nicotine dependence treatment
Ashare, R. L., Falcone, M., & Lerman, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.034 · Cited by 170
“Galantamine has some beneficial effects on cognition and drug use in stimulant abusers (Sofuoglu and Carroll, 2011; Sofuoglu and Mooney, 2009; Sofuoglu et al., 2011) and may improve inhibitory control in abstinent”
Metadata
- Authors
- Sofuoglu, M., & Mooney, M.
- Venue
- CNS Drugs
- Published
- 2009-11
- Volume
- 23
- Issue
- 11
- Pages
- 939-952
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2042249181
- Cited by
- 72
- References
- 18
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholinergic Functioning in Stimulant Addiction: Implications for Medications Development. https://app.cochat.ai/papers/10.2165/11310920-000000000-00000
- The paper
- Sofuoglu, M., & Mooney, M. (2009). Cholinergic Functioning in Stimulant Addiction: Implications for Medications Development. CNS Drugs. https://doi.org/10.2165/11310920-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.